Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.

Saved in:

Bibliographic Details
Title:	Drug-associated dermatomyositis following ipilimumab therapy: a novel immune-mediated adverse event associated with cytotoxic T-lymphocyte antigen 4 blockade.
Authors:	Sheik Ali S; King's College London School of Medicine, London, England., Goddard AL; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Center for Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Luke JJ; Melanoma Disease Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Donahue H; Melanoma Disease Center, Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Todd DJ; Division of Rheumatology, Immunology, and Allergy, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts., Werchniak A; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts3Center for Cutaneous Oncology, Dana Farber Cancer Institute, Boston, Massachusetts., Vleugels RA; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Source:	JAMA dermatology [JAMA Dermatol] 2015 Feb; Vol. 151 (2), pp. 195-9.
Publication Type:	Case Reports; Journal Article
Journal Info:	Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	2168-6084
DOI:	10.1001/jamadermatol.2014.2233